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History
Warfarin, one of the vitamin K antagonists (VKAs), has 
been used since 1940, when it was first approved for the 
treatment of venous thromboembolism (VTE).[1] The 
first novel anticoagulant (NOAC) and direct thrombin 
inhibitor (DTI), lepirudin, originates from 1998, when its intravenous 
form was approved for the use of clinically relevant heparin-induced 
thrombocytopenia (HIT).[2] Ximelgatran, the first oral DTI, had a similar 
clinical efficacy to warfarin, but was withdrawn from the market in 2006 
owing to an increased risk of liver toxicity.[3,4] Dabigatran came to the 
fore in 2009 after the publication of the RE-LY trial in the New England 
Journal of Medicine.[5] This landmark study compared two different doses 
of dabigatran, 110 mg and 150 mg given twice daily, versus warfarin, in 
patients with non-valvular atrial fibrillation (NVAF). In summary, this 
non-inferiority trial showed that dabigatran administered at 150 mg twice 
daily was associated with lower rates of stroke and systemic embolisation. 
However, similar rates of major haemorrhage were observed. The RE-LY 
trial was followed in 2011 by the ROCKET-AF trial, validating the use of 
rivaroxaban versus warfarin in NVAF. This large randomised controlled 
trial of more than 14 000 patients confirmed the non-inferiority of 
rivaroxaban versus warfarin in preventing stroke or systemic embolisation. 
While there were similar side-effect profiles in each group, the rivaroxaban 
group appeared to have less intracranial and fatal bleeding. Similar results 
were shown with apixaban in the ARISTOTLE trial in 2011.[6] 
Mechanism of action
Thrombin is central to the clotting cascade and converts fibrinogen to 
fibrin, thereby creating the framework for clot formation. Thrombin 
has a number of positive feedback loops that enhance its effect 
by increasing the effects of factors V, VIII and XI, and also has a 
procoagulant effect on platelets.[7,8] Furthermore, its procoagulant 
effects activate factor XIII, which enhances the formation of bonds 
between fibrin, thereby aiding clot stabilisation. The advantage of 
DTIs over the indirect thrombin inhibitors such as the heparins is 
that they are not dependent on antithrombin III. As such, the DTIs 
can inhibit both free and bound thrombin.[9] 
Rivaroxaban, apixaban and edoxaban are very specific antagonists 
of activated factor Xa, which directly converts prothrombin to 
thrombin, thus leading to clot formation. Thrombin, in turn, goes 
on to activate the platelets necessary for the development of a mature 
clot. Because of the amplifying nature of the clotting cascade, a single 
molecule of factor Xa is able to generate more than 1 000 molecules of 
thrombin. Moreover, factor Xa bound to prothrombinase is 300 000 
times more active than unbound factor Xa.[10] In summary, activation 
and binding of factor Xa create a ‘clotting explosion’, generating 
massive amounts of thrombin. 
Pharmacokinetics
Dabigatran, the prototypical DTI, is a small, highly lipophilic molecule 
that is rapidly absorbed from the gastrointestinal tract (GIT).[11] 
Dabigatran undergoes extensive hydrolysis by serum esterases, 
resulting in only 7% bioavailability.[12] Dabigatran is predominantly 
metabolised by the kidneys, with 80% being renally excreted as an 
unchanged molecule.[12] The mean half-life of dabigatran is 8 hours 
after a single dose and up to 14 hours with multiple twice-daily 
dosing.[13] As dabigatran is renally eliminated, the half-life increases 
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dramatically to >24 hours once the creatinine clearance decreases to 
<30 ml/min.[14] 
Factor Xa inhibitors are small molecules that are rapidly absorbed, 
have good bioavailability after absorption and are highly protein 
bound, making elimination by dialysis difficult. The factor Xa 
inhibitors are slightly different from the DTIs in that they are 
predominantly metabolised in the liver, with 50 - 73% of the dose of 
the former being excreted via the liver.[15]
An often overlooked pharmacokinetic property of dabigatran and 
the other factor Xa inhibitors is the effect of an efflux pump on the 
luminal aspect of the gastrointestinal mucosa. This efflux permeability 
glycoprotein transporter pump (P-gp) exports dabigatran back into 
the lumen of the GIT.[13] It would therefore make sense that P-gp 
inhibitors such as amiodarone, verapamil and quinidine increase 
the serum concentrations of dabigatran. Conversely, rifampicin, an 
enzyme-inducer, lowers plasma concentrations by up to 66%.[16]
Monitoring
Warfarin has a narrow therapeutic window with a wide variability 
in anticoagulant effect, the latter being highly inter- and intrapatient 
variable.[17] Despite appropriate monitoring, 30 - 50% of international 
normalised ratios (INRs) remain outside the therapeutic window.[18] 
One of the main benefits of the pharmacokinetic profile of dabigatran 
is its predictable renal excretion, with low inter- and intra-individual 
variability.[11] Clinically, this characteristic allows renal-based dosing 
without routine monitoring, which is a significant advantage over 
the VKAs. Dabigatran affects the prothrombin time (PT) and INR, 
but this is not predictable. While it also affects the activated partial 
thromboplastin time (aPTT), the concentration-response curve 
flattens out at higher concentrations and therefore becomes less 
reliable.[19] 
Similar pharmacokinetic and monitoring profiles have been found 
with the other NOACs) such as rivaroxaban and apixaban.[20] While 
factor Xa inhibitors do affect the PT, this is unpredictable and 
unreliable as a quantitative marker of the degree of anticoagulation.
Reversal
Currently, there are no specific reversal agents for dabigatran or the 
factor Xa inhibitors. As mentioned above, even multidose dabigatran 
has a relatively short half-life. The most prudent course of action in 
reversing the effects of the DTIs is to stop administering the agent. 
The DTIs, including dabigatran, have relatively low protein binding 
properties; hence a significant amount may be removed during a 
short session of dialysis.[11] Considering the mechanism of action 
of the DTIs, it would be appropriate to administer recombinant 
activated factor VII or prothrombin concentrates. However, these 
interventions are very expensive and not readily available. 
Reversal of VKAs for urgent or invasive surgical procedures is 
always difficult. Guidelines recommend discontinuing VKAs and 
starting low molecular weight heparin (LMWH),[11] the latter being 
discontinued periprocedurally. This results in an approximately 
2-week window period during which the patient has variable 
interruptions in systemic anticoagulation. Interesting results were 
obtained in the RE-LY trial, analysing a subgroup of patients on 
dabigatran or warfarin who required an invasive procedure. Patients 
receiving warfarin were off systemic anticoagulation for a mean of 
114 hours. There was no difference in the rates of periprocedural 
bleeding.[21] In patients requiring emergency surgery, there was a 
trend to more favourable outcomes in those receiving dabigatran.[21] 
The results of a randomised controlled trial (BRUISE-CONTROL) 
of bridging therapy with warfarin versus continuous anticoagulation 
should provide more direction in the area.[11] 
Indications and evidence 
Atrial fibrillation
Atrial fibrillation (AF) is the commonest arrhythmia, with an 
overall prevalence of 5.5%, increasing up to almost 18% in patients 
>85 years of age.[22] AF is a well-known risk factor for stroke and 
increases stroke risk approximately 5-fold.[23] More than 20% of 
strokes are attributable to AF. The 30-day mortality risk is as high 
as 28% if the condition is left untreated.[24] VKAs have been the 
standard of care to reduce future risk of stroke. Warfarin decreased 
the risk of cerebrovascular accidents (CVAs) by 67% and 37% 
compared with placebo and antiplatelet therapy, respectively.[25] A 
recent meta-analysis of 50 000 patients requiring anticoagulation 
for AF provided good evidence for the use of NOACs, with an 
overall reduction of 11% in mortality and cardiovascular system 
(CVS)-specific mortality. The number needed to treat (NNT) to 
prevent one death overall and one cardiovascular death was 244 
and 500, respectively.[25] Large trials such as the RE-LY (dabigatran), 
ROCKET-AF (rivaroxaban) and ARISTOTLE (apixaban) provide the 
data supporting the use of NOACs in secondary stroke prevention in 
NVAF. These trials excluded patients with prosthetic valves, mitral 
stenosis and decompensated heart failure who may have needed valve 
replacement. The data from these landmark trials cannot therefore be 
applied to these clinical scenarios. The most recent trial (ENGAGE 
TIMI-AF 48 trial), studying one of the NOACs (edoxaban), showed 
non-inferiority of high- and low-dose edoxaban compared with 
warfarin, but less bleeding and fewer safety end-points in the 
investigational product groups.[26]
Currently, there are no ‘head-to-head’ trials comparing dabigatran, 
rivaroxaban, apixaban and edoxaban. A recent meta-analysis suggests 
that NOACs are not more effective than warfarin in the secondary 
prevention of strokes in cases of NVAF. Importantly though, there seems 
to be a lower risk of intracranial bleeding. In one specific meta-analysis, 
there did not appear to be a difference in mortality rates.[27] Conflicting 
data exist and other meta-analyses advocate the use of NOACs, stating 
that they are more efficacious than warfarin for the prevention of 
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stroke and systemic embolisation, with a decreased risk of intracranial 
haemorrhage. There is clearly a knowledge gap that requires a large, 
comparative, randomised controlled trial to answer these questions. 
There are no data to support the use of NOACs in patients with a prior 
history of intracranial, intraocular, spinal, retroperitoneal and intra-
articular bleeding, as such patients were excluded.[5,6,28]
Many of the large trials, such as RE-LY and ROCKET-AF, excluded 
major strokes as well as early strokes in their enrolment of subjects 
for these novel agents. There seems to be limited literature supporting 
the early use of these agents in preventing recurrent CVAs or transient 
ischaemic attacks (TIAs) in patients with AF. A small study reviewed 
41 patients who were started on NOACs at a median of 2 days and 
showed no increase in the incidence of intracranial haemorrhage. 
However, further data are needed.
In patients who are not candidates for warfarin for stroke prevention 
in the setting of NVAF, aspirin is often used as an alternative. The 
AVERROES trial reviewed the use of apixaban versus aspirin in this 
specific group of patients. The study was discontinued early as there 
was a clear benefit in favour of apixaban, with similar rates of major 
bleeding episodes for the two drugs.[29]
There is much debate about whether these agents are cost-effective, 
particularly in resource-constrained environments. These costs 
may be US$3 000 per annum for NOACs and US$48 per annum 
for warfarin.[17] Even taking into account the cost of INR testing 
and provider visits, the NOACs may be prohibitively expensive. 
The efficacy data are often clouded by the many single-centre 
small studies that have often reported no overall or cardiovascular 
mortality benefit for dabigatran. 
The risk profile for major bleeding events seemed to be agent 
specific. Dabigatran and apixaban were associated with reduced rates 
of major bleeding, while rivaroxaban was not. [25] Recent evidence in 
the ENGAGE TIMI-AF 48 trial suggests that edoxaban is not inferior 
to warfarin with regard to stroke prevention and that it is significantly 




There is mounting evidence for the use of dabigatran as a DTI to 
prevent VTE. The RE-MODEL and RE-NOVATE trials showed that 
once-daily dabigatran was not inferior to enoxaparin.[30,31] There were 
no significant differences in the rates of bleeding complications in 
either knee or hip replacement.
The RECORD-4 trial provided evidence for the use of rivaroxaban 
prophylaxis in the setting of total knee arthroplasty and was found to 
be superior to twice-daily enoxaparin in VTE prophylaxis following 
knee arthroplasty. 
The ADVANCE study showed that apixaban was non-inferior 
to twice-daily enoxaparin in thromboprophylaxis for knee and 
hip arthroplasty.[32] However, apixaban was superior to once-daily 
enoxaparin for thromboprophylaxis, with no difference in bleeding 
events with knee and hip arthroplasty.[32,33]
Venous thrombosis is common in medical patients. Untreated, 
the incidence of venographically detected thrombosis is about 15%. 
Unfractionated heparin and LMWH have both been validated for 
thromboprophylaxis in the medical setting.[34,35] They are highly 
efficacious, safe, and cost-effective.[36] The role of NOACs in chemical 
thromboprophylaxis has also been studied. The ADOPT trial was a 
double-blinded, double-dummy trial comparing apixaban with daily 
enoxaparin. While there were fewer patients who met the criteria for 
the primary outcome in the apixaban group, this was not statistically 
significant. Furthermore, by day 30, there was a significant increase 
in bleeding complications, including both major and clinically 
significant non-major bleeding.[37] The MAGELLAN study reviewed 
a similar role for rivaroxaban in chemical thromboprophylaxis and 
it would appear that the investigational group showed a reduced 
rate of thrombo-embolic events. However, this group was treated 
significantly longer than the control arm that received enoxaparin (35 
days of rivaroxaban versus 10 days of enoxaparin).[38] These studies 
may raise more questions than answers. 
Management of confirmed VTE
Dabigatran has also been studied in acute VTE. The RECOVER-I 
and -II trials showed that fixed-dose management of the condition 
with dabigatran was non-inferior to warfarin and did not require the 
intensive monitoring necessary with VKAs.[39,40] 
In patients diagnosed with symptomatic deep vein thrombosis 
(DVT) as well as pulmonary thrombo-embolus (PTE), oral 
rivaroxaban was non-inferior to warfarin, with similar rates of 
bleeding.[41,42] Similar evidence now exists for the use of fixed-dose 
apixaban to treat VTE.[43] 
Acute coronary syndromes
Major adverse cardiovascular events (MACEs) are common after 
acute coronary syndromes (ACSs), notwithstanding optimal care.[44] 
This is possibly due to the high platelet reactivity, despite dual 
antiplatelet therapy (DAPT), which may persist for weeks to months 
after the event.[45,46] While warfarin has been studied as an antiplatelet 
adjunct post-ACS, this drug had an unacceptable bleeding risk even 
though it lowered the rate of MACEs.[47] It is therefore important to 
investigate the role of NOACs in DAPT to prevent MACEs post-ACS. 
A significant amount of data is now available to study the effects of 
dabigatran, rivaroxaban, apixaban and darexaban. The addition of 
NOACs in this setting would seem to confer an unacceptably high 
risk of haemorrhage, with a 2 - 4-fold increase in the risk of bleeding. 
There appears to be no clinically significant benefit to the addition of 
NOACs to DAPT. Further investigation is required to clearly delineate 
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of warfarin, clopidogrel, aspirin, NOACs and new generation P2Y12-
receptor inhibitors, such as prasugrel and ticagrelor. 
Conclusion
While warfarin and other VKAs have been the gold standard of 
anticoagulation for over half a decade, the evolution of NOACs has been 
met with much excitement and has stimulated renewed interest and 
ongoing research. While biologically attractive, the clinical role of these 
agents raises many questions regarding how best to integrate them into 
current treatment regimens. NOACs are more convenient, reliable and 
predictable than the gold standard. Limitations of using these agents 
include the cost, lack of a reversal agent and lack of reliable monitoring. 
With the evidence at hand and considering the cost implications of these 
drugs, the use of NOACs in a resource-constrained environment seems 
limited. Should the utility of convenience outweigh the real risks and cost 
implications of NOACs? The evidence seems to speak for itself. 
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